Watch TGTX. Know when insiders buy.
One email the day a filing lands. Free.
TGTX
TG THERAPEUTICS, INC.
53.20
−1.33 −2.44%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
44
WATCH · insiders 37, shorts 50
Insiders, 90 days
−$275K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $8.1BP/E 19.3DIV YIELD —FCF YIELD 0.21%REV TTM $799.5M +76.1%NET INCOME $441.5M +630.2%NET CASH $382.2M52W 26.94 – 59.06SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $240.3M | +70.3% | 82.9% | $21.7M | $7.8M | −72.4% | 0.05 | $39.3M | $293K | $39M | Aug 5 |
| Q1 2026 · Mar 31 | $204.9M | +69.6% | 83.6% | $34.8M | $19.8M | +290.8% | 0.12 | −$17.9M | $51K | −$17.9M | Aug 5 |
| Q4 2025 · Dec 31derived | $192.6M | +78.0% | 80.2% | $50.5M | $23M | −1.3% | 0.15 | $19.7M | $67K | $19.6M | Feb 27 |
| Q3 2025 · Sep 30 | $161.7M | +92.8% | 82.6% | $29.4M | $390.9M | +9974.6% | 2.43 | −$23.2M | $80K | −$23.2M | Nov 5 |
| Q2 2025 · Jun 30 | $141.1M | +92.1% | 86.6% | $34.8M | $28.2M | +309.8% | 0.17 | $7.4M | $42K | $7.4M | Aug 5 |
| Q1 2025 · Mar 31 | $120.9M | +90.4% | 87.1% | $8.6M | $5.1M | — | 0.03 | −$28.7M | $25K | −$28.7M | Aug 5 |
| Q4 2024 · Dec 31derived | $108.2M | +146.0% | 85.8% | $29.9M | $23.3M | — | 0.15 | −$25.6M | $21K | −$25.7M | Feb 27 |
| Q3 2024 · Sep 30 | $83.9M | −49.4% | 88.9% | $12.4M | $3.9M | −96.6% | 0.02 | −$12.2M | $24K | −$12.2M | Nov 5 |
| Q2 2024 · Jun 30 | $73.5M | — | 88.7% | $8.8M | $6.9M | — | 0.04 | $5.5M | $0 | $5.5M | Nov 5 |
| Q1 2024 · Mar 31 | $63.5M | — | 91.4% | −$9.3M | −$10.7M | — | -0.07 | −$8.2M | $0 | −$8.2M | Nov 5 |
| Q4 2023 · Dec 31derived | $44M | — | 82.1% | −$12.5M | −$14.4M | — | -0.10 | −$13.2M | $0 | −$13.2M | Feb 27 |
| Q3 2023 · Sep 30 | $165.8M | — | 97.9% | $114.8M | $113.9M | — | 0.73 | $83.7M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $616.3M | 83.7% | $123.3M | $447.2M | 72.6% | 2.77 | −$24.8M | $214K | −$25M | — | — |
| FY2024 · to Dec 31 | $329M | 88.3% | $41.9M | $23.4M | 7.1% | 0.15 | −$40.5M | $45K | −$40.6M | — | — |
| FY2023 · to Dec 31 | $233.7M | 94.0% | $20.6M | $12.7M | 5.4% | 0.09 | −$31.4M | $0 | −$31.4M | — | — |
| FY2022 · to Dec 31 | $2.8M | 90.5% | −$218.3M | −$223.8M | -8036.3% | -1.65 | −$176.2M | $14K | −$176.2M | — | — |
| FY2021 · to Dec 31 | $6.7M | 88.2% | −$344.8M | −$348.1M | -5204.1% | -2.63 | −$295.6M | $401K | −$296M | — | — |
| FY2020 · to Dec 31 | $152K | — | −$273.6M | −$279.4M | -183803.3% | -2.42 | −$214.5M | $357K | −$214.9M | — | — |
Every number comes from TG THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.